PD-L1 antibody (FITC)
Quick Overview for PD-L1 antibody (FITC) (ABIN7648459)
Target
See all PD-L1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
- 
    
- 
                                            
Purpose
 - FITC-Linked Anti-Programmed Cell Death Protein 1 Ligand 1 (PDL1) Polyclonal Antibody
 - 
                                            
Purification
 - Antigen-specific affinity chromatography followed by Protein A affinity chromatography
 - 
                                            
Isotype
 - IgG
 
 - 
                                            
 - 
    
 - 
    
- 
                                            
Application Notes
 - For flow cytometry, the suggested use of this reagent is 1-5 μL per 10^6 cells in 100 μL volume. Optimal working dilutions could be determined by end user.
 - 
                                            
Restrictions
 - For Research Use only
 
 - 
                                            
 - 
    
- 
                                            
Format
 - Liquid
 - 
                                            
Buffer
 - 0.01M PBS, pH 7.4, containing 0.05 % Proclin-300, 50 % glycerol.
 - 
                                            
Preservative
 - ProClin
 - 
                                            
Precaution of Use
 - This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
 - 
                                            
Storage
 - 4 °C
 - 
                                            
Storage Comment
 - Store at 4°C, protected from prolonged exposure to light.
 
 - 
                                            
 - 
    
- PD-L1 (CD274 (PD-L1))
 - 
                                            
Alternative Name
 - Programmed Cell Death Protein 1 Ligand 1
 - 
                                            
Background
 - CD274, PDCD1LG1, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1-LG1, Programed Death Ligand 1
 - 
                                            
UniProt
 - Q9NZQ7
 - 
                                            
Pathways
 - Cancer Immune Checkpoints
 
Target
 -